浙江杭州一A股个护上市企业被传内斗再激化。8月25日，可靠股份（301009.SZ）发布的公告显示，在公司近日召开的董事会会 议上，该公司创始人兼董事长金利伟的前妻鲍佳对多份议案投反对票，并指出金利伟随意投资亏损企业、强行主导的业务持续亏 损、公司拟聘任的副总经理兼董秘专业能力存疑等。 不过，针对鲍佳的观点，可靠股份均在公告中予以说明，并最终通过上述议案。在社交平台上，网友对此称"前妻手撕新董秘""炮 轰可靠股份不可靠"等，8月26日，南都湾财社记者发送采访邮件至可靠股份官方及董秘处，截至发稿前未得到回应。同日，记者 多次致电可靠股份，电话未能接通。 值得注意的是，8月26日晚间，可靠股份发布公告称，因关联交易信息披露违规，该司于当日收到浙江证监局出具的警示函，创 始人金利伟及财务总监李超楠被监管谈话。 新副总经理兼董秘专业性存疑？ 创始人前妻称他更适合当董事长秘书 杭州可靠护理用品股份有限公司（下称"可靠股份"）成立于2001年，专注婴儿护理用品、成人失禁用品和宠物卫生用品等，拥有 可靠、吸收宝等多个品牌。 8月25日，可靠股份发布公告称，该公司于8月21日召开了董事会会议表决4份议案，会议由金利伟主持，7 ...

8月24日晚间，可靠股份发布公告，8月21日举行的公司第五届董事会第十一次会议上，担 任董事的鲍佳对本次会议四项议案中的三项投了反对票。 具体来看，对于《关于2025年半年度报告及其摘要》的议案，表决结果为同意6票，反对1 票，弃权0票。鲍佳对该议案投反对票，理由是关联交易违规已进入调查阶段、阻碍股东履 行权力已进入调查阶段、原经营决策的失职。 其他议案中，关于《关于聘任公司副总经理的议案》和《关于聘任公司董事会秘书的议 案》，分别有1票反对和1票弃权，均由董事鲍佳反对，独立董事景乃权弃权。 离婚超一年，可靠股份（301009.SZ)实控人金利伟和前妻鲍佳间的斗争还在持续。 鲍佳 图片来源：可靠股份微信公众号 新董秘上任即遭"炮轰" 公开资料显示，鲍佳是可靠股份董事长兼总经理金利伟的前妻。两人于2024年2月离婚 后，鲍佳卸任上市公司总经理但仍保留董事席位，截至2025年6月末，她直接持有可靠股 份29.13%的股份，位列公司第二大股东。同期，第一大股东金利伟的直接持股比例为 30.13%。 在王向亭之前，俞文斌、王万元、谢丽红先后担任过公司董秘，履职时间最短的仅半年左 右，其间，身为公司董事长的金利伟多次代 ...

Core Viewpoint - The ongoing conflict between the controlling shareholder Jin Liwei and his ex-wife Bao Jia at Reliable Shares (301009.SZ) continues to escalate, particularly regarding the appointment of the new secretary and concerns over corporate governance and compliance issues [1][4]. Group 1: Board Meeting and Voting - On August 21, during the 11th meeting of the 5th board of directors, Bao Jia voted against three out of four proposals, including the appointment of Wang Xiangting as the new vice president and board secretary, citing concerns over his qualifications and potential risks [1][3]. - Despite Bao Jia's objections and the independent director Jing Naiquan abstaining from voting on some proposals, all relevant motions were ultimately passed [1][3]. Group 2: New Secretary's Background - Wang Xiangting was appointed as the new board secretary after a series of frequent changes in this position since the company's IPO in June 2021, with previous secretaries serving very short tenures [2]. - Prior to joining Reliable Shares, Wang had experience as a board secretary at other listed companies but had not worked in a securities role for several years [2][3]. Group 3: Concerns Over Wang Xiangting's Competence - Bao Jia criticized Wang's lack of familiarity with current securities regulations and his reliance on the securities department for completing tasks, leading to errors in board documents [3][4]. - There were complaints about Wang's attitude towards assisting employees with stock-related matters, which Bao Jia viewed as obstructive to the board's functioning [3][4]. Group 4: Related Party Transactions and Compliance Issues - Bao Jia raised alarms about potential violations regarding related party transactions, noting that transactions in Q1 2025 exceeded the regulatory threshold of 300,000 yuan and 0.5% of the company's audited net assets [5][6]. - The Zhejiang Securities Regulatory Bureau is currently investigating these transactions, which occurred shortly after Wang's appointment, raising questions about his accountability [5][6]. Group 5: Company Performance and Governance Issues - The performance of Reliable Shares has been a point of contention, with Bao Jia accusing Jin Liwei of making poor investment decisions, including investing in a loss-making company [7]. - Since its IPO, the company's profitability has significantly declined, with a notable loss in 2022, although there has been some recovery in 2023 [7].

华夏时报记者张玫北京报道 对此，《华夏时报》曾发布《涉事双方独家回应！量化私募创始人遭"背刺"出局？基金清盘、股东会议笼罩疑云》，报道了该公司核心高层的内斗、部分 基金产品清盘以及股东会议程序争议等焦点事件。 报道显示，靖奇投资曾发布公告称范思奇因健康原因离职，但范思奇否认此说法，声称自己遭到"背刺"，股东会议在"没有任何书面讨论的情况下单方面 罢免其全部职务"。 彼时，范思奇称，自己仍是靖奇公司的最大股东及法定代表人；而靖奇投资一位管理层人士表示，剩余股东已签署了一致行动人，公司实控人为唐靖人。 上海靖奇投资管理有限公司(下称"靖奇投资")的高层内斗有了新动态。曾经的"好哥们"——靖奇投资的创始人范思奇与联合创始人、股东唐靖人又"开 撕"了。 8月3日，范思奇连发两条朋友圈，刺破了资本市场的平静，其称，"公司账上的500万，被一笔笔转空，账户只剩了两千多块"。 4天后(8月7日)，范思奇方面又发布声明称："公司遭遇非法使用伪造法人印章及冒用法定代表人签名的严重违规行为。未经法定代表人范思奇授权的基金 设立、清盘及证券账户开立等操作均属无效。" "我们原先是好哥们，这很令人唏嘘。"唐靖人对《华夏时报》记者表示 ...

曾被誉为"同学创业典范"的三雄极光，如今因公司"内斗"被推至聚光灯下。 近日，在三雄极光董事长换届以及管理层聘任的董事会议案中，暴露出了该公司董事会的内部分歧。据 三雄极光公告，在公司投票选举董事长时，出现了两个提案：一、选张宇涛；二、选张贤庆。当时提案 一获得了7票同意2票反对，反对票来自其中的两名创始人——张贤庆和陈松辉。当时张贤庆反对的理由 是，"张宇涛在任期间管理混乱。" 这次董事会上的针锋相对，意味着昔日"华工四兄弟"的分歧已从幕后走向台前。 "同学创业典范" 曾几何时，三雄极光是校友共同创业的典范之一。1991年，张宇涛、张贤庆、林岩这三位毕业于华南理 工大学无线电工程系的同级校友在毕业后选择了自主创业。1993年，同校校友陈松辉加入，形成了延续 至今的"四驾马车"的格局。 很快，几个创始人成功研发出了电子镇流器产品，并在广州番禺的一处农田旁建厂生产。这款产品上市 后，大获成功。通过对电子镇流器产品的研发和生产，1993年，公司注册了"三雄"商标。其后四人在 1996年创立"极光"品牌，2008年，三雄极光成功中标北京奥运会包括"鸟巢"在内的多个场馆照明工程， 从此一炮而红并奠定了其在工程照明领域 ...

Core Viewpoint - The internal conflict within Kexing Biologics has intensified, particularly surrounding a significant cash dividend distribution, which has become a focal point for shareholder disputes and board control [1][10]. Group 1: Shareholder Disputes - Kexing Biologics is experiencing a power struggle between two factions led by Li Jiaqiang and Yin Weidong, with the latter being one of the company's founders [5]. - A special shareholders' meeting was held to elect a new board, proposed by Sequoia Capital, which resulted in the dismissal of the current board and the election of ten new members [3][5]. - Li Jiaqiang's faction claims the election is invalid, asserting that the meeting was improperly conducted and that their board remains the only legitimate governing body [6][8]. Group 2: Dividend Distribution - Kexing Biologics announced a total cash dividend of $7.448 billion, with an initial payment of $55 per share, which is expected to deplete over 70% of the company's cash reserves [10][11]. - The dividend distribution is seen as a compensatory measure for shareholders, particularly for Li Jiaqiang's faction, who have not received direct dividends from the operational entity, Beijing Kexing Zhongwei [11][12]. - The distribution has sparked controversy, with opposing factions accusing each other of attempting to manipulate the situation for personal gain [12]. Group 3: Regulatory and Compliance Issues - Kexing Biologics faces potential delisting from NASDAQ if it fails to submit a compliance plan by the deadline [13]. - The company is currently working to restore its stock trading and appoint a new auditing firm to address regulatory concerns [13].

Core Viewpoint - The article discusses the internal conflicts within Sinovac Biotech, highlighting the company's significant financial performance and the ongoing power struggle among its shareholders and board members [5][18][21]. Group 1: Company Overview - Sinovac Biotech, known for its COVID-19 vaccine, has reported revenues exceeding 130 billion yuan and a net profit of over 96 billion yuan from 2021 to 2022, resulting in a net profit margin of approximately 73.8% [11][16]. - The company has been suspended from trading for six years due to internal disputes, indicating ongoing governance issues [21]. Group 2: Shareholder Conflict - A recent shareholder meeting in Antigua and Barbuda involved a proposal to remove current board members and elect new candidates nominated by SAIF Partners, reflecting deep divisions among shareholders [18][22]. - The company announced a massive special dividend payment of up to 7.5 billion USD, leaving it with 2.8 billion USD in cash after the distribution [22][23]. Group 3: Historical Context - The founder, Weidong Yin, has a background in public health and has been pivotal in the company's development since its establishment in 2001 [42][62]. - Sinovac's history includes rapid advancements in vaccine development, notably during the SARS outbreak, which laid the groundwork for its later success with COVID-19 vaccines [60][61].

Core Viewpoint - The internal conflicts within Kailitai (300326.SZ) continue, with significant disagreements over the election of the new chairman, management changes, and the contentious share repurchase issue, leading to potential risks for the company [1][2][14]. Group 1: Internal Conflicts - The board of directors' election revealed deep divisions between the second-largest shareholder and the first and third shareholders, affecting key decisions such as the chairman's election and management appointments [1][3]. - The new chairman, Cai Zhongxi, was elected with 4 votes against 3 for the candidate Wang Chong, representing the first and third shareholders [1][5]. - Management changes included the appointment of Xia Tian as the general manager and Guo Haibo as the board secretary, amidst disagreements over these appointments [1][7]. Group 2: Share Repurchase Disputes - The ongoing dispute regarding the share repurchase from Ligetai has resurfaced, with the board previously voting to issue a repurchase notice, but the decision faced opposition from key stakeholders [8][10]. - The board's recent meeting did not pass the proposal to send a repurchase notice, with votes split and some members calling for more information before making a decision [9][11]. - The repurchase agreement was triggered due to Ligetai's failure to complete an IPO by December 31, 2024, leading to legal actions from the second-largest shareholder [8][12]. Group 3: Internal Control Issues - Kailitai is facing internal control problems, with auditors unable to obtain sufficient evidence regarding the valuation of equity investments and related party transactions, leading to a "non-standard" audit opinion for the 2024 financial report [2][14]. - The company announced a delay in the disclosure of its 2024 annual report due to significant disagreements with auditors, which may result in further regulatory scrutiny [14][15]. Group 4: Shareholder Actions - The second-largest shareholder, represented by Yuan Zheng and Wang Zhengmin, has been increasing their stake in Kailitai, now holding approximately 6.38% of the shares, which is close to the first shareholder's 6.99% [15][16]. - The ongoing increase in shareholding indicates a potential power struggle for control and influence over Kailitai's strategic direction [16].

Core Viewpoint - The internal conflict between the core management of Zhenxin Technology and its controlling shareholder, Chengdu Guoteng Electronics Group, has intensified, leading to the rejection of key proposals at the annual shareholder meeting [2][3]. Group 1: Shareholder Meeting and Proposals - The annual shareholder meeting of Zhenxin Technology took place on April 22, where several key proposals, including the 2024 Board of Directors' work report, were rejected due to opposition from Guoteng Group [3][4]. - Guoteng Group's chairman, Gao Hong, opted for online voting to avoid potential disputes at the meeting, indicating the tense atmosphere surrounding the event [3][4]. - The rejection of the proposals highlights the ongoing conflict between the management and the controlling shareholder, with questions raised about how to address the rejected proposals moving forward [3][4]. Group 2: Reasons for Opposition - Gao Hong criticized the board for failing to act in the best interests of the company and its shareholders, citing a 44% decline in net profit while the chairman received a 10.6% salary increase [4]. - Concerns were raised about potential conflicts of interest regarding board members' connections to other companies with similar business operations [4]. Group 3: Shareholder Dynamics - Guoteng Group holds 29.21% of Zhenxin Technology's shares, with the actual control resting with He Yan, who holds 51% of the shares, leading to claims of decision-making being "hijacked" by minority shareholders [5][6]. - The management expressed frustration over the lack of communication and cooperation from Guoteng Group, while Guoteng Group countered that they have been cooperative when it benefits the company [6][8]. Group 4: Future Outlook and Demands - The management of Zhenxin Technology desires the dissolution of Guoteng Group to achieve a more decentralized ownership structure, which would eliminate a controlling shareholder [7][8]. - Guoteng Group's stance is focused on stability and development, advocating for lawful governance and adherence to regulations by all shareholders [8][9].